Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients

Rheumatoid arthritis (RA) patients are currently treated with biological agents mostly aimed at cytokine blockade, such as tumor necrosis factor-alpha (TNFα). Currently, there are no biomarkers to predict therapy response to these agents. Here, we aimed to predict response to adalimumab (ADA) treatm...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Frontiers in immunology Ročník 14; s. 1303231
Hlavní autoři:	Hageman, Ishtu, Mol, Femke, Atiqi, Sadaf, Joustra, Vincent, Sengul, Hilal, Henneman, Peter, Visman, Ingrid, Hakvoort, Theodorus, Nurmohamed, Mike, Wolbink, Gertjan, Levin, Evgeni, Li Yim, Andrew Y.F., D’Haens, Geert, de Jonge, Wouter J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 22.12.2023
Témata:	adalimumab Adalimumab - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers DNA methylation Epigenome Humans Immunology machine learning rheumatoid arthritis therapy response Tumor Necrosis Factor-alpha DNA methylation machine learning rheumatoid arthritis therapy response adalimumab
ISSN:	1664-3224, 1664-3224
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!